AB&B BIO-TECH-B(02627): The application for the market approval of trivalent influenza virus subunit vaccine has been approved by the National Medical Products Administration.

AB&B BIO-TECH-B (02627) announcement, the China National Medical Products Administration has approved the Group's new drug application for a trivalent influenza virus subunit vaccine for all age groups. As of the date of this announcement, this vaccine has become the first and only trivalent influenza virus subunit vaccine approved for marketing for all populations in China. This product has been significantly improved upon traditional virus split vaccines, with advantages such as comprehensive protection, high purity of antigen components, and low risk of adverse reactions.